Why DBV Technologies (DBVT) Stock Is Skyrocketing

DBV Technologies SA – ADR DBVT, a clinical-stage biopharmaceutical company focused on pediatric allergies, announced a financing deal of up to $306.9 million (€284.5 million). The stock is up some 50% to $5.90 during Friday’s session following the deal.

What To Know: The company will receive $125.5 million (€116.3 million) upon closing, with an additional $181.4 million (€168.2 million) possible if all warrants are exercised.

The funding will support working capital, the Viaskin Peanut program, a potential Biologics License Application, and a U.S. launch if approved. The financing, led by major healthcare investors, could dilute existing shareholders by up to 73.7%.

CEO Daniel Tassé highlighted the company's alignment with the FDA on safety data, potentially expediting the BLA submission. The Phase 3 VITESSE study, exceeding enrollment expectations, aims for results in fourth-quarter 2025.

Read Also: What’s Going On With Ford Stock?

How To Buy DBVT Stock

By now you're likely curious about how to participate in the market for DBV Technologies – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, DBVT has a 52-week high of $8.32 and a 52-week low of $2.20.